{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Clinical trials", "GP IIb/IIa antagonists", "Glycoproteins IIb/IIIa", "Paradoxical thrombosis", "Platelets"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36637623", "DateCompleted": {"Year": "2023", "Month": "04", "Day": "13"}, "DateRevised": {"Year": "2023", "Month": "04", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "01", "Day": "13"}], "Language": ["eng"], "ELocationID": ["10.1007/s40292-023-00562-9"], "Journal": {"ISSN": "1179-1985", "JournalIssue": {"Volume": "30", "Issue": "2", "PubDate": {"Year": "2023", "Month": "Mar"}}, "Title": "High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension", "ISOAbbreviation": "High Blood Press Cardiovasc Prev"}, "ArticleTitle": "An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives.", "Pagination": {"StartPage": "93", "EndPage": "107", "MedlinePgn": "93-107"}, "Abstract": {"AbstractText": ["The glycoprotein (GP) IIb/IIIa receptor is found integrin present in platelet aggregations. GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived thrombus formation through the competition with fibrinogen and von Willebrand factor. Currently, three parenteral GP IIb/IIIa competitors (tirofiban, eptifibatide, and abciximab) are approved for clinical use in patients affected by percutaneous coronary interventions (PCI) in the location of acute coronary syndrome (ACS). GP IIb/IIIa antagonists have their mechanism of action in platelet aggregation prevention, distal thromboembolism, and thrombus formation, whereas the initial platelet binding to damage vascular areas is preserved. This work is aimed to provide a comprehensive review of the significance of GP IIb/IIIa inhibitors as a sort of antiplatelet agent. Their mechanism of action is based on factors that affect their efficacy. On the other hand, drugs that inhibit GP IIb/IIIa already approved by the FDA were reviewed in detail. Results from major clinical trials and regulatory practices and guidelines to deal with GP IIb/IIIa inhibitors were deeply investigated. The cardiovascular pathology and neuro-interventional surgical application of GP IIb/IIIa inhibitors as a class of antiplatelet agents were developed in detail. The therapeutic risk/benefit balance of currently available GP IIb/IIa receptor antagonists is not yet well elucidated in patients with ACS who are not clinically evaluated regularly for early cardiovascular revascularization. On the other hand, in patients who have benefited from PCI, the antiplatelet therapy intensification by the addition of a GP IIb/IIIa receptor antagonist (intravenously) may be an appropriate therapeutic strategy in reducing the occurrence of risks of thrombotic complications related to the intervention. Development of GP IIb/IIIa inhibitors with oral administration has the potential to include short-term antiplatelet benefits compared with intravenous GP IIb/IIIa inhibitors for long-term secondary preventive therapy in cardiovascular disease. But studies showed that long-term oral administration of GP IIb/IIIa receptor inhibitors has been ineffective in preventing ischemic events. Paradoxically, they have been linked to a high risk of side effects by producing prothrombotic and pro-inflammatory events."], "CopyrightInformation": "\u00a9 2023. Italian Society of Hypertension."}, "AuthorList": [{"Identifier": ["0000-0002-7301-8151"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador. javad.sharifirad@gmail.com."}], "LastName": "Sharifi-Rad", "ForeName": "Javad", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "V.I. Nikitin Chemistry Institute of the National Academy of Sciences of Tajikistan, Ayni 299/2, 734063, Dushanbe, Tajikistan."}], "LastName": "Sharopov", "ForeName": "Farukh", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt."}, {"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), 6th October, 12566, Egypt."}], "LastName": "Ezzat", "ForeName": "Shahira M", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Analytical and Food Chemistry, Faculty of Pharmacy, Al-Andalus University for Medical Sciences, 35XQ+C2F, Tartous, Syria."}], "LastName": "Zam", "ForeName": "Wissam", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Functional Foods, Nutraceuticals and Phytomedicine Unit, Department of Biochemistry, Federal University of Technology, Akure, Akure, 340252, Nigeria."}], "LastName": "Ademiluyi", "ForeName": "Adedayo Oluwaseun", "Initials": "AO"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Federal University, Oye-Ekiti, Oye-Ekiti, 371104, Nigeria."}, {"Identifier": [], "Affiliation": "Microbiology, Biotechnology and Nanotechnology Laboratory, Department of Microbiology, Edo University Iyamho, Iyamho, Edo, Nigeria."}], "LastName": "Oyeniran", "ForeName": "Olubukola Helen", "Initials": "OH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Microbiology, Biotechnology and Nanotechnology Laboratory, Department of Microbiology, Edo University Iyamho, Iyamho, Edo, Nigeria."}], "LastName": "Adetunji", "ForeName": "Charles Oluwaseun", "Initials": "CO"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Anatomy, College of Basic Medical Science, Edo University Iyamho, Iyamho, Nigeria."}], "LastName": "Roli", "ForeName": "Osahon Itohan", "Initials": "OI"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute for Medicinal Plants Research \"Dr. Josif Pan\u010di\u0107\", Tadeu\u0161a Ko\u0161\u0107u\u0161ka 1, 11000, Belgrade, Serbia."}], "LastName": "\u017divkovi\u0107", "ForeName": "Jelena", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for Healthy Living, University of Concepci\u00f3n, 4070386, Concepci\u00f3n, Chile. martorellpons@gmail.com."}], "LastName": "Martorell", "ForeName": "Miquel", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania."}], "LastName": "Docea", "ForeName": "Anca Oana", "Initials": "AO"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Histology, Embryology, and Cytogenetic, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, 10100, Rabat, Morocco."}], "LastName": "El Omari", "ForeName": "Nasreddine", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Mohammed V University in Rabat, Rabat, Morocco."}], "LastName": "Bouyahya", "ForeName": "Abdelhakim", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Centro Tecnol\u00f3gico de la Carne de Galicia, R\u00faa Galicia N\u00ba 4, Parque Tecnol\u00f3gico de Galicia, 32900, San Cibrao das Vinas, Spain."}, {"Identifier": [], "Affiliation": "Facultade de Ciencias, \u00c1rea de Tecnolox\u00eda dos Alimentos, Universidade de Vigo, 32004, Ourense, Spain."}], "LastName": "Lorenzo", "ForeName": "Jos\u00e9 M", "Initials": "JM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania. calinadaniela@gmail.com."}], "LastName": "Calina", "ForeName": "Daniela", "Initials": "D"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "High Blood Press Cardiovasc Prev", "NlmUniqueID": "9421087", "ISSNLinking": "1120-9879"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Platelet Aggregation Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Platelet Membrane Glycoprotein IIb"}, {"RegistryNumber": "0", "NameOfSubstance": "Platelet Glycoprotein GPIIb-IIIa Complex"}, {"RegistryNumber": "X85G7936GV", "NameOfSubstance": "Abciximab"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Platelet Aggregation Inhibitors"}, {"QualifierName": [], "DescriptorName": "Percutaneous Coronary Intervention"}, {"QualifierName": [], "DescriptorName": "Platelet Membrane Glycoprotein IIb"}, {"QualifierName": [], "DescriptorName": "Platelet Glycoprotein GPIIb-IIIa Complex"}, {"QualifierName": [], "DescriptorName": "Abciximab"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Puddu PE, Iannetta L, Placanica A, Cuturello D, Schiariti M, Manfrini O. The role of Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and the interference with anemia. Int J Cardiol. 2016;222:1091\u20136.", "ArticleIdList": ["27522492", "10.1016/j.ijcard.2016.07.207"]}, {"Citation": "Shattil SJ. Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways. Thromb Haemost. 1999;82(2):318\u201325.", "ArticleIdList": ["10605720"]}, {"Citation": "Goldschmidt-Clermont PJ, Shear WS, Schwartzberg J, Varga CF, Bray PF. Clues to the death of an Olympic champion. Lancet. 1996;347(9018):1833.", "ArticleIdList": ["8667943", "10.1016/S0140-6736(96)91652-9"]}, {"Citation": "Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334(17):1090\u20134.", "ArticleIdList": ["8598867", "10.1056/NEJM199604253341703"]}, {"Citation": "Walter DH, Sch\u00e4chinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997;350(9086):1217\u20139.", "ArticleIdList": ["9652563", "10.1016/S0140-6736(97)05399-3"]}, {"Citation": "Grove EL, \u00d8rntoft TF, Lassen JF, Jensen HK, Kristensen SD. The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction. J Intern Med. 2004;255(6):637\u201344.", "ArticleIdList": ["15147527", "10.1111/j.1365-2796.2004.01327.x"]}, {"Citation": "Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72(1):325\u201338.", "ArticleIdList": ["6308050", "1129188", "10.1172/JCI110973"]}, {"Citation": "Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;98(8):734\u201341.", "ArticleIdList": ["9727542", "10.1161/01.CIR.98.8.734"]}, {"Citation": "Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PC, et al. Percutaneous coronary intervention in the current era compared with 1985\u20131986: the National Heart, Lung, and Blood Institute Registries. Circulation. 2000;102(24):2945\u201351.", "ArticleIdList": ["11113044", "10.1161/01.CIR.102.24.2945"]}, {"Citation": "Armstrong PC, Peter K. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again. Thromb Haemost. 2012;107(05):808\u201314.", "ArticleIdList": ["22370973", "10.1160/TH11-10-0727"]}, {"Citation": "Investigators E. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352(9122):87\u201392.", "ArticleIdList": ["10.1016/S0140-6736(98)06113-3"]}, {"Citation": "Investigators E. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330(14):956\u201361.", "ArticleIdList": ["10.1056/NEJM199404073301402"]}, {"Citation": "Investigators E. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336(24):1689\u201396.", "ArticleIdList": ["10.1056/NEJM199706123362401"]}, {"Citation": "Wojciechowski VV, Calina D, Tsarouhas K, Pivnik AV, Sergievich AA, Kodintsev VV, et al. A guide to acquired vitamin K coagulophathy diagnosis and treatment: the Russian perspective. Daru. 2017;25(1):10.", "ArticleIdList": ["28416008", "5393004", "10.1186/s40199-017-0175-z"]}, {"Citation": "Calina D, Sarkar C, Arsene AL, Salehi B, Docea AO, Mondal M, et al. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. Immunol Res. 2020;68(6):315\u201324.", "ArticleIdList": ["33006053", "7529090", "10.1007/s12026-020-09154-4"]}, {"Citation": "Sharifi-Rad J, Quispe C, Shaheen S, El Haouari M, Azzini E, Butnariu M, et al. Flavonoids as potential anti-platelet aggregation agents: from biochemistry to health promoting abilities. Crit Rev Food Sci Nutr. 2022;62(29):8045\u201358.", "ArticleIdList": ["33983094", "10.1080/10408398.2021.1924612"]}, {"Citation": "Bianchi S, Maloberti A, Peretti A, Garatti L, Palazzini M, Occhi L, et al. Determinants of functional improvement after cardiac rehabilitation in acute coronary syndrome. High Blood Pressure Cardiovasc Prevent. 2021;28(6):579\u201387.", "ArticleIdList": ["10.1007/s40292-021-00473-7"]}, {"Citation": "Kohli S, Shahzad K, Jouppila A, Holth\u00f6fer H, Isermann B, Lassila R. Thrombosis and inflammation\u2014a dynamic interplay and the role of glycosaminoglycans and activated protein C. Front Cardiovasc Med. 2022;9: 866751.", "ArticleIdList": ["35433860", "9008778", "10.3389/fcvm.2022.866751"]}, {"Citation": "Cugno M, Tedeschi A. Coagulation factor autoantibodies. In: Shoenfeld Y, Meroni PL, Gershwin ME, editors. Autoantibodies. San Diego: Elsevier; 2014. p. 499\u2013509.", "ArticleIdList": ["10.1016/B978-0-444-56378-1.00059-9"]}, {"Citation": "Gragnano F, Sperlongano S, Golia E, Natale F, Bianchi R, Crisci M, et al. The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy. Mediators Inflamm. 2017;2017:5620314.", "ArticleIdList": ["28634421", "5467347", "10.1155/2017/5620314"]}, {"Citation": "Hassan MI, Saxena A, Ahmad F. Structure and function of von Willebrand factor. Blood Coagul Fibrinolysis. 2012;23(1):11\u201322.", "ArticleIdList": ["22089939", "10.1097/MBC.0b013e32834cb35d"]}, {"Citation": "Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E. Evolution of replacement therapy for von Willebrand disease: from plasma fraction to recombinant von Willebrand factor. Blood Rev. 2019;38: 100572.", "ArticleIdList": ["31229334", "10.1016/j.blre.2019.04.001"]}, {"Citation": "Feghhi S, Munday AD, Tooley WW, Rajsekar S, Fura AM, Kulman JD, et al. Glycoprotein Ib-IX-V complex transmits cytoskeletal forces that enhance platelet adhesion. Biophys J. 2016;111(3):601\u20138.", "ArticleIdList": ["27508443", "4982925", "10.1016/j.bpj.2016.06.023"]}, {"Citation": "Fiodorenko-Dumas \u017b, Dumas I, Mastej K, Jakobsche-Policht U, Bittner J, Adamiec R. Receptor GP IIb/IIIa as an indicator of risk in vascular events. Clin Appl Thromb Hemost. 2019;25:1076029619845056-.", "ArticleIdList": ["31185733", "6714900", "10.1177/1076029619845056"]}, {"Citation": "Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfus. 2011;9(Suppl 2):s3\u20138.", "ArticleIdList": ["21839029", "3159913"]}, {"Citation": "Aguila S, Lavin M, Dalton N, Patmore S, Chion A, Trahan GD, et al. Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood. 2019;133(14):1585\u201396.", "ArticleIdList": ["30770394", "10.1182/blood-2018-09-874636"]}, {"Citation": "Yang M, Huo X, Miao Z, Wang Y. Platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute ischemic stroke. Drugs. 2019;79(5):515\u201329.", "ArticleIdList": ["30838514"]}, {"Citation": "Kurtz L, Kao L, Newman D, Kurtz I, Zhu Q. Integrin \u03b1IIb\u03b23 Inside-out activation: an in situ conformational analysis reveals a new mechanism. J Biol Chem. 2012;287(27):23255\u201365.", "ArticleIdList": ["22613710", "3391112", "10.1074/jbc.M112.360966"]}, {"Citation": "Ma Y-Q, Qin J, Plow EF. Platelet integrin \u03b1IIb\u03b23: activation mechanisms. J Thromb Haemostasis. 2007;5(7):1345\u201352.", "ArticleIdList": ["10.1111/j.1538-7836.2007.02537.x"]}, {"Citation": "Durrant TN, van den Bosch MT, Hers I. Integrin \u03b1IIb\u03b23 outside-in signaling. Blood. 2017;130(14):1607\u201319.", "ArticleIdList": ["28794070", "5672329", "10.1182/blood-2017-03-773614"]}, {"Citation": "Gil M. Overview of the coagulation system. In: Shaz B, Hillyer C, Gil M, editors. Transfusion medicine and hemostasis clinical and laboratory aspects. 3rd ed. Elsevier: Amsterdam; 2019. p. 559\u201364."}, {"Citation": "Calina D, Buga AM, Mitroi M, Buha A, Caruntu C, Scheau C, et al. The treatment of cognitive, behavioural and motor impairments from brain injury and neurodegenerative diseases through cannabinoid system modulation-evidence from in vivo studies. J Clin Med. 2020;9(8):28.", "ArticleIdList": ["10.3390/jcm9082395"]}, {"Citation": "Tanase A, Colita A, Ianosi G, Neagoe D, Branisteanu DE, Calina D, et al. Rare case of disseminated fusariosis in a young patient with graft vs. host disease following an allogeneic transplant. Exp Ther Med. 2016;12(4):2078\u201382.", "ArticleIdList": ["27698695", "5038475", "10.3892/etm.2016.3562"]}, {"Citation": "Aloizou AM, Siokas V, Pateraki G, Liampas I, Bakirtzis C, Tsouris Z, et al. Thinking outside the Ischemia Box: advancements in the use of multiple sclerosis drugs in ischemic stroke. J Clin Med. 2021;10(4):630.", "ArticleIdList": ["33562264", "7914575", "10.3390/jcm10040630"]}, {"Citation": "Sharifi-Rad J, Cruz-Martins N, L\u00f3pez-Jornet P, Lopez EP-F, Harun N, Yeskaliyeva B, et al. Natural coumarins: exploring the pharmacological complexity and underlying molecular mechanisms. Oxid Med Cell Longev. 2021;2021:6492346.", "ArticleIdList": ["34531939", "8440074", "10.1155/2021/6492346"]}, {"Citation": "Grech ED. Percutaneous coronary intervention. I: History and development. BMJ. 2003;326(7398):1080.", "ArticleIdList": ["12750213", "1125993", "10.1136/bmj.326.7398.1080"]}, {"Citation": "Capuano E, Marchese F, Capuano R, Piramide N, Palumbo R, Simonis V, et al. The burden of cardio-cerebrovascular risk factors: differences between individual risk and population risk. High Blood Pressure Cardiovasc Prevent. 2021;28(6):597\u2013603.", "ArticleIdList": ["10.1007/s40292-021-00477-3"]}, {"Citation": "Tocci G, Muiesan ML, Volpe M. Hypertension management and control in Italy: a real-world survey in elderly patients. High Blood Pressure Cardiovasc Prevent. 2021;28(5):425\u20136.", "ArticleIdList": ["10.1007/s40292-021-00471-9"]}, {"Citation": "Gim\u00e9nez-Bastida JA, Boeglin WE, Boutaud O, Malkowski MG, Schneider C. Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation. Faseb J. 2019;33(1):1033\u201341.", "ArticleIdList": ["30096040", "10.1096/fj.201801018R"]}, {"Citation": "Gregorini L, Marco J, Fajadet J, Bernies M, Cassagneau B, Brunel P, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol. 1997;29(1):13\u201320.", "ArticleIdList": ["8996289", "10.1016/S0735-1097(96)00428-7"]}, {"Citation": "Gulec S, Ozdol C, Vurgun K, Selcuk T, Turhan S, Duzen V, et al. The effect of high-dose aspirin pre-treatment on the incidence of myonecrosis following elective coronary stenting. Atherosclerosis. 2008;197(1):171\u20136.", "ArticleIdList": ["17434171", "10.1016/j.atherosclerosis.2007.03.010"]}, {"Citation": "Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet. 1999;353(9148):227\u201331.", "ArticleIdList": ["9923894", "10.1016/S0140-6736(98)11086-3"]}, {"Citation": "Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344(25):1888\u201394.", "ArticleIdList": ["11419425", "10.1056/NEJM200106213442502"]}, {"Citation": "Yang J, Ma Y-Q, Page RC, Misra S, Plow EF, Qin J. Structure of an integrin \u03b1IIb\u03b23 transmembrane-cytoplasmic heterocomplex provides insight into integrin activation. Proc Natl Acad Sci. 2009;106(42):17729\u201334.", "ArticleIdList": ["19805198", "2764936", "10.1073/pnas.0909589106"]}, {"Citation": "Eisenberg PR, Ghigliotti G. Platelet-dependent and procoagulant mechanisms in arterial thrombosis. Int J Cardiol. 1999;68(Suppl 1):S3-10.", "ArticleIdList": ["10328604", "10.1016/S0167-5273(98)00284-8"]}, {"Citation": "Becker RC. Thrombosis and the role of the platelet. Am J Cardiol. 1999;83(9):3\u20136.", "ArticleIdList": ["10.1016/S0002-9149(99)00083-1"]}, {"Citation": "Schneider DJ. Anti-platelet therapy: glycoprotein IIb-IIIa antagonists. Br J Clin Pharmacol. 2011;72(4):672\u201382.", "ArticleIdList": ["21906121", "3195742", "10.1111/j.1365-2125.2010.03879.x"]}, {"Citation": "Kristensen SD, W\u00fcrtz M, Grove EL, De Caterina R, Huber K, Moliterno DJ, et al. Contemporary use of glycoprotein IIb/IIIa inhibitors. Thromb Haemost. 2012;107(02):215\u201324.", "ArticleIdList": ["22234385", "10.1160/TH11-07-0468"]}, {"Citation": "Knight CJ, Panesar M, Wright C, Clarke D, Butowski PS, Patel D, et al. Altered platelet function detected by flow cytometry: effects of coronary artery disease and age. Arterioscler Thromb Vasc Biol. 1997;17(10):2044\u201353.", "ArticleIdList": ["9351370", "10.1161/01.ATV.17.10.2044"]}, {"Citation": "Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost. 1997;77(04):748\u201354.", "ArticleIdList": ["9134654", "10.1055/s-0038-1656045"]}, {"Citation": "Wagner CL, Mascelli M, Neblock D, Weisman H, Coller B, Jordan R. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88(3):907\u201314.", "ArticleIdList": ["8704248", "10.1182/blood.V88.3.907.907"]}, {"Citation": "Bihour C, Durrieu-Ja\u00efs C, Macchi L, Poujol C, Coste P, Besse P, et al. Expression of markers of platelet activation and the interpatient variation in response to abciximab. Arterioscler Thromb Vasc Biol. 1999;19(2):212\u20139.", "ArticleIdList": ["9974400", "10.1161/01.ATV.19.2.212"]}, {"Citation": "Investigators P. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol. 1998;32(7):2003\u201310.", "ArticleIdList": ["10.1016/S0735-1097(98)00474-4"]}, {"Citation": "Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99(21):2720\u201332.", "ArticleIdList": ["10351964", "10.1161/01.CIR.99.21.2720"]}, {"Citation": "Danzi GB, Sesana M, Capuano C, Mauri L, Predolini S, Baglini R. Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention. Int J Cardiol. 2006;107(2):241\u20136.", "ArticleIdList": ["16412804", "10.1016/j.ijcard.2005.03.025"]}, {"Citation": "Viswanathan G, Kidambi A, Nelson A, Mayurathan G, Hardy J, Kesteven P, et al. Glycoprotein IIb/IIIa inhibitor associated severe thrombocytopenia in patients with coronary artery disease: clinical course and outcomes. Platelets. 2012;23(3):224\u20138.", "ArticleIdList": ["21913813", "10.3109/09537104.2011.604804"]}, {"Citation": "Schiariti M, Saladini P, Cuturello D, Iannetta L, Torromeo C, Puddu PE. Decline in platelet count and long-term post-PCI ischemic events: implication of the intra-aortic balloon pump. Vascul Pharmacol. 2014;60(1):25\u201331.", "ArticleIdList": ["24239797", "10.1016/j.vph.2013.11.002"]}, {"Citation": "Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects. Clin Pharmacol Ther. 2002;71(3):186\u201395.", "ArticleIdList": ["11907493", "10.1067/mcp.2002.121775"]}, {"Citation": "Jeremias A, Bhatt DL, Chew DP, Ziada KM, Albirini A, Brener SJ, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol. 2002;89(10):1209\u201311.", "ArticleIdList": ["12008179", "10.1016/S0002-9149(02)02308-1"]}, {"Citation": "Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997;80(4A):11B-20B.", "ArticleIdList": ["9291241", "10.1016/S0002-9149(97)00572-9"]}, {"Citation": "Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996;27(3):536\u201342.", "ArticleIdList": ["8606262", "10.1016/0735-1097(95)00500-5"]}, {"Citation": "Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist. Clin Pharmacokinet. 2002;41(3):187\u201395.", "ArticleIdList": ["11929319", "10.2165/00003088-200241030-00003"]}, {"Citation": "Dornbos D 3rd, Katz JS, Youssef P, Powers CJ, Nimjee SM. Glycoprotein IIb/IIIa inhibitors in prevention and rescue treatment of thromboembolic complications during endovascular embolization of intracranial aneurysms. Neurosurgery. 2018;82(3):268\u201377.", "ArticleIdList": ["28472526", "10.1093/neuros/nyx170"]}, {"Citation": "Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102(2):149\u201356.", "ArticleIdList": ["10889124", "10.1161/01.CIR.102.2.149"]}, {"Citation": "O\u2019Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med. 2000;342(18):1316\u201324.", "ArticleIdList": ["10793164", "10.1056/NEJM200005043421803"]}, {"Citation": "Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation. 2001;103(24):2891\u20136.", "ArticleIdList": ["11413076", "10.1161/01.CIR.103.24.2891"]}, {"Citation": "Tamhane UU, Gurm HS. The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opin Drug Saf. 2008;7(6):809\u201319.", "ArticleIdList": ["18983227", "10.1517/14740330802500353"]}, {"Citation": "Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Andersen HR, et al. 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv. 2009;2(10):909\u201316.", "ArticleIdList": ["19850248", "10.1016/j.jcin.2009.07.009"]}, {"Citation": "Fischer F, Buxy S, Kurz DJ, Eberli FR, Senn O, Zbinden R, et al. Efficacy and safety of abbreviated eptifibatide treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2021;139:15\u201321.", "ArticleIdList": ["33065082", "10.1016/j.amjcard.2020.09.054"]}, {"Citation": "Zeymer U, Wienbergen H. A review of clinical trials with eptifibatide in cardiology. Cardiovasc Drug Rev. 2007;25(4):301\u201315.", "ArticleIdList": ["18078431"]}, {"Citation": "Marso SP, Bhatt DL, Roe MT, Houghtaling PL, Labinaz M, Kleiman NS, et al. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation. 2000;102(24):2952\u20138.", "ArticleIdList": ["11113045", "10.1161/01.CIR.102.24.2952"]}, {"Citation": "Han B, Ma T, Liu Z, Wu Y, Tan W, Sun S, et al. Efficacy and safety of tirofiban in clinical patients with acute ischemic stroke. Front Neurol. 2021;12: 785836.", "ArticleIdList": ["35211073", "10.3389/fneur.2021.785836"]}, {"Citation": "Servoss SJ, Wan Y, Snapinn SM, DiBattiste PM, Zhao XQ, Theroux P, et al. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. Am J Cardiol. 2004;93(7):843\u20137.", "ArticleIdList": ["15050486", "10.1016/j.amjcard.2003.12.021"]}, {"Citation": "Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108(4):399\u2013406.", "ArticleIdList": ["12874182", "10.1161/01.CIR.0000084501.48570.F6"]}, {"Citation": "Dooley M, Goa KL. Sibrafiban. Drugs. 1999;57(2):225\u201330 (discussion 31\u20132).", "ArticleIdList": ["10188763", "10.2165/00003495-199957020-00012"]}, {"Citation": "Nicholson NS, Abood NA, Panzer-Knodle SG, Frederick LG, Page JD, Salyers AK, et al. Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev. 2001;21(3):211\u201326.", "ArticleIdList": ["11301411", "10.1002/med.1007"]}, {"Citation": "Kamran H, Jneid H, Kayani WT, Virani SS, Levine GN, Nambi V, et al. Oral antiplatelet therapy after acute coronary syndrome: a review. JAMA. 2021;325(15):1545\u201355.", "ArticleIdList": ["33877270", "10.1001/jama.2021.0716"]}, {"Citation": "Neumann FJ, Zohlnh\u00f6fer D, Fakhoury L, Ott I, Gawaz M, Sch\u00f6mig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol. 1999;34(5):1420\u20136.", "ArticleIdList": ["10551687", "10.1016/S0735-1097(99)00350-2"]}, {"Citation": "Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003;107(8):1123\u20138.", "ArticleIdList": ["12615789", "10.1161/01.CIR.0000053559.46158.AD"]}, {"Citation": "Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. 2000;284(12):1549\u201358.", "ArticleIdList": ["11000650", "10.1001/jama.284.12.1549"]}, {"Citation": "The PRISM-PLUS investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338(21):1488\u201397.", "ArticleIdList": ["10.1056/NEJM199805213382102"]}, {"Citation": "The PURSUIT Trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339(7):436\u201343.", "ArticleIdList": ["10.1056/NEJM199808133390704"]}, {"Citation": "Boersma E, Akkerhuis KM, Th\u00e9roux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100(20):2045\u20138.", "ArticleIdList": ["10562258", "10.1161/01.CIR.100.20.2045"]}, {"Citation": "Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357(9272):1915\u201324.", "ArticleIdList": ["11425411", "10.1016/S0140-6736(00)05060-1"]}, {"Citation": "Tardiff BE, Jennings LK, Harrington RA, Gretler D, Potthoff RF, Vorchheimer DA, et al. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation. 2001;104(4):399\u2013405.", "ArticleIdList": ["11468200", "10.1161/hc2901.093500"]}, {"Citation": "Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction\u2013summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40(7):1366\u201374.", "ArticleIdList": ["12383588", "10.1016/S0735-1097(02)02336-7"]}, {"Citation": "Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients\u2019 data with long-term follow-up. Eur Heart J. 2007;28(4):443\u20139.", "ArticleIdList": ["17251257", "10.1093/eurheartj/ehl472"]}, {"Citation": "Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358(21):2205\u201317.", "ArticleIdList": ["18499565", "10.1056/NEJMoa0706816"]}, {"Citation": "Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003;24(1):28\u201366.", "ArticleIdList": ["12559937", "10.1016/S0195-668X(02)00618-8"]}, {"Citation": "Boersma E, Harrington RA, Moliterno DJ, White H, Th\u00e9roux P, Van de Werf F, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. The Lancet. 2002;359(9302):189\u201398.", "ArticleIdList": ["10.1016/S0140-6736(02)07442-1"]}, {"Citation": "Kastrati A, Mehilli J, Neumann F-J, Dotzer F, ten Berg J, Bollwein H, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295(13):1531\u20138.", "ArticleIdList": ["16533938", "10.1001/jama.295.13.joc60034"]}, {"Citation": "Schiariti M, Saladini A, Missiroli B, Papalia F, Cuturello D, Puddu PE, et al. Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant\u2019ANna TIrofiban Safety study. J Cardiovasc Med. 2010;11(4):250\u20139.", "ArticleIdList": ["10.2459/JCM.0b013e328334c7b9"]}, {"Citation": "Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol. 2002;90(12):1421\u20133.", "ArticleIdList": ["12480064", "10.1016/S0002-9149(02)02892-8"]}, {"Citation": "Investigators E. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (London, England). 2000;356(9247):2037.", "ArticleIdList": ["10.1016/S0140-6736(00)03400-0"]}, {"Citation": "Danzi GB, Sesana M, Capuano C, Mauri L, Berra Centurini P, Baglini R. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol. 2004;94(1):35\u20139.", "ArticleIdList": ["15219505", "10.1016/j.amjcard.2004.03.026"]}, {"Citation": "Bilsel T, Akbulut T, Yesilcimen K, Terzi S, Sayar N, Dayi SU, et al. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty. Heart Vessels. 2006;21(2):102\u20137.", "ArticleIdList": ["16550311", "10.1007/s00380-005-0870-4"]}, {"Citation": "Marmur JD, Poludasu S, Lazar J, Cavusoglu E. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2009;73(2):214\u201321.", "ArticleIdList": ["19156882", "10.1002/ccd.21773"]}, {"Citation": "O\u2019Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention the ESPRIT trial: a randomized controlled trial. JAMA. 2001;285(19):2468\u201373.", "ArticleIdList": ["11368699", "10.1001/jama.285.19.2468"]}, {"Citation": "Schiariti M, Saladini A, Cuturello D, Missiroli B, Puddu PE. Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention. J Cardiovasc Med. 2011;12(1):29\u201336.", "ArticleIdList": ["10.2459/JCM.0b013e32833cdd04"]}, {"Citation": "NICE guidance. NICE guidance (National Institute for Health and Care Excellence. https://www.nice.org.uk/ . 2021."}, {"Citation": "Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet glycoprotein IIb-IIIa in unstable angina: receptor suppression using integrilin therapy. Am J Cardiol. 1997;80(4a):34b-b38.", "ArticleIdList": ["9291244", "10.1016/S0002-9149(97)00575-4"]}, {"Citation": "Gurbel PA, Bliden KP, Saucedo JF, Suarez TA, DiChiara J, Antonino MJ, et al. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. J Am Coll Cardiol. 2009;53(8):648\u201357.", "ArticleIdList": ["19232896", "10.1016/j.jacc.2008.10.045"]}, {"Citation": "Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98(25):2829\u201335.", "ArticleIdList": ["9860783", "10.1161/01.CIR.98.25.2829"]}, {"Citation": "Chandler AB, Earhart AD, Speich HE, Kueter TJ, Hansen J, White MM, et al. Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients. Thromb Res. 2010;125(1):44\u201352.", "ArticleIdList": ["19487018", "10.1016/j.thromres.2009.04.017"]}, {"Citation": "Moser M, Bertram U, Peter K, Bode C, Ruef J. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol. 2003;41(4):586\u201392.", "ArticleIdList": ["12658060", "10.1097/00005344-200304000-00011"]}, {"Citation": "Thiele H, Schindler K, Friedenberger J, Eitel I, F\u00fcrnau G, Grebe E, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008;118(1):49\u201357.", "ArticleIdList": ["18559698", "10.1161/CIRCULATIONAHA.107.747642"]}, {"Citation": "K\u0131rma C, Erkol A, Pala S, Oduncu V, D\u00fcndar C, \u0130zgi A, et al. Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2012;79(1):59\u201367.", "ArticleIdList": ["21523892", "10.1002/ccd.23109"]}, {"Citation": "Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation. 2010;121(6):784\u201391.", "ArticleIdList": ["20124127", "10.1161/CIRCULATIONAHA.109.882746"]}, {"Citation": "Deibele AJ, Kirtane AJ, Pinto DS, Lucca MJ, Neva C, Shui A, et al. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Thrombolysis. 2006;22(1):47\u201350.", "ArticleIdList": ["16786232", "10.1007/s11239-006-7454-8"]}, {"Citation": "Hassan W, Al-Sergani H, Al Buraiki J, Dunn B, Al Turki F, Akhras N, et al. Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study. Am Heart J. 2007;154(2):345\u201351.", "ArticleIdList": ["17643587", "10.1016/j.ahj.2007.04.020"]}, {"Citation": "Iantorno M, Shlofmitz E, Rogers T, Torguson R, Kolm P, Gajanana D, et al. Should non-ST-elevation myocardial infarction be treated like ST-elevation myocardial infarction with shorter door-to-balloon time? Am J Cardiol. 2020;125(2):165\u20138.", "ArticleIdList": ["31740021", "10.1016/j.amjcard.2019.10.012"]}, {"Citation": "Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. 2000;35(6):1535\u201342.", "ArticleIdList": ["10807457", "10.1016/S0735-1097(00)00581-7"]}, {"Citation": "Moliterno DJ. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee. Am Heart J. 2000;139(4):563\u20136.", "ArticleIdList": ["10740135", "10.1016/S0002-8703(00)90031-0"]}, {"Citation": "Howard JP, Jones DA, Gallagher S, Rathod K, Antoniou S, Wright P, et al. Glycoprotein IIb/IIIa inhibitors use and outcome after percutaneous coronary intervention for non-ST elevation myocardial infarction. Biomed Res Int. 2014;2014: 643981.", "ArticleIdList": ["24895595", "4034401", "10.1155/2014/643981"]}, {"Citation": "Kaku S, Umemura K, Mizuno A, Yano S, Suzuki K, Kawasaki T, et al. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis. Eur J Pharmacol. 1998;345(2):185\u201392.", "ArticleIdList": ["9600636", "10.1016/S0014-2999(98)00005-3"]}, {"Citation": "Choudhri TF, Hoh BL, Zerwes HG, Prestigiacomo CJ, Kim SC, Connolly ES Jr, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Investig. 1998;102(7):1301\u201310.", "ArticleIdList": ["9769322", "508977", "10.1172/JCI3338"]}, {"Citation": "Meyer FB, Morita A, Puumala MR, Nichols DA. Medical and surgical management of intracranial aneurysms. Mayo Clin Proc. 1995;70(2):153\u201372.", "ArticleIdList": ["7845041", "10.4065/70.2.153"]}, {"Citation": "Yue W. Endovascular treatment of unruptured intracranial aneurysms. Interv Neuroradiol. 2011;17(4):420\u20134.", "ArticleIdList": ["22192544", "3296500", "10.1177/159101991101700404"]}, {"Citation": "Wiebers DO, Whisnant JP, Huston J 3rd, Meissner I, Brown RD Jr, Piepgras DG, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378):103\u201310.", "ArticleIdList": ["12867109", "10.1016/S0140-6736(03)13860-3"]}, {"Citation": "Brisman JL, Song JK, Newell DW. Cerebral aneurysms. N Engl J Med. 2006;355(9):928\u201339.", "ArticleIdList": ["16943405", "10.1056/NEJMra052760"]}, {"Citation": "Brown RD Jr, Huston J, Hornung R, Foroud T, Kallmes DF, Kleindorfer D, et al. Screening for brain aneurysm in the Familial Intracranial Aneurysm study: frequency and predictors of lesion detection. J Neurosurg. 2008;108(6):1132\u20138.", "ArticleIdList": ["18518716", "4190025", "10.3171/JNS/2008/108/6/1132"]}, {"Citation": "Rordorf G, Bellon RJ, Budzik RE Jr, Farkas J, Reinking GF, Pergolizzi RS, et al. Silent thromboembolic events associated with the treatment of unruptured cerebral aneurysms by use of Guglielmi detachable coils: prospective study applying diffusion-weighted imaging. AJNR Am J Neuroradiol. 2001;22(1):5\u201310.", "ArticleIdList": ["11158880", "7975528"]}, {"Citation": "Brooks NP, Turk AS, Niemann DB, Aagaard-Kienitz B, Pulfer K, Cook T. Frequency of thromboembolic events associated with endovascular aneurysm treatment: retrospective case series. J Neurosurg. 2008;108(6):1095\u2013100.", "ArticleIdList": ["18518710", "10.3171/JNS/2008/108/6/1095"]}, {"Citation": "Grossberg JA, Hanel RA, Dabus G, Keigher K, Haussen DC, Sauvageau E, et al. Treatment of wide-necked aneurysms with the Low-profile Visualized Intraluminal Support (LVIS Jr) device: a multicenter experience. J Neurointerv Surg. 2017;9(11):1098\u2013102.", "ArticleIdList": ["27789790", "10.1136/neurintsurg-2016-012687"]}, {"Citation": "Cohen JE, Gomori JM, Leker RR, Spektor S, Abu El Hassan H, Itshayek E. Stent and flow diverter assisted treatment of acutely ruptured brain aneurysms. J Neurointerv Surg. 2018;10(9):851\u20138.", "ArticleIdList": ["29778996", "10.1136/neurintsurg-2017-013742"]}, {"Citation": "Yang P, Zhao K, Zhou Y, Zhao R, Zhang L, Zhao W, et al. Stent-assisted coil placement for the treatment of 211 Acutely ruptured wide-necked intracranial aneurysms: a single-center 11-year experience. Radiology. 2015;276(2):545\u201352.", "ArticleIdList": ["25822469", "10.1148/radiol.2015140974"]}, {"Citation": "Brinjikji W, Morales-Valero SF, Murad MH, Cloft HJ, Kallmes DF. Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis. AJNR Am J Neuroradiol. 2015;36(1):121\u20135.", "ArticleIdList": ["25082819", "7965919", "10.3174/ajnr.A4066"]}, {"Citation": "Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: part I-Pathophysiological and pharmacological features. Neurosurgery. 2000;46(6):1344\u201359.", "ArticleIdList": ["10834640", "10.1097/00006123-200006000-00012"]}, {"Citation": "Grunwald IQ, Papanagiotou P, Politi M, Struffert T, Roth C, Reith W. Endovascular treatment of unruptured intracranial aneurysms: occurrence of thromboembolic events. Neurosurgery. 2006;58(4):612\u20138 (discussion -8).", "ArticleIdList": ["16575324", "10.1227/01.NEU.0000204101.00996.D9"]}, {"Citation": "Ryu CW, Park S, Shin HS, Koh JS. Complications in stent-assisted endovascular therapy of ruptured intracranial aneurysms and relevance to antiplatelet administration: a systematic review. AJNR Am J Neuroradiol. 2015;36(9):1682\u20138.", "ArticleIdList": ["26138136", "7968784", "10.3174/ajnr.A4365"]}, {"Citation": "Muto M, Giurazza F, Ambrosanio G, Vassallo P, Briganti F, Tecame M, et al. Stent-assisted coiling in ruptured cerebral aneurysms: multi-center experience in acute phase. Radiol Med. 2017;122(1):43\u201352.", "ArticleIdList": ["27631680", "10.1007/s11547-016-0686-6"]}, {"Citation": "Samaniego EA, Gibson E, Nakagawa D, Ortega-Gutierrez S, Zanaty M, Roa JA, et al. Safety of tirofiban and dual antiplatelet therapy in treating intracranial aneurysms. Stroke Vasc Neurol. 2019;4(1):36\u201342.", "ArticleIdList": ["31105977", "6475079", "10.1136/svn-2018-000192"]}, {"Citation": "Ostrowska M, Adamski P, Kozi\u0144ski M, Navarese EP, Fabiszak T, Grze\u015bk G, et al. Off-target effects of glycoprotein IIb/IIIa receptor inhibitors. Cardiol J. 2014;21(5):458\u201364.", "ArticleIdList": ["24526503", "10.5603/CJ.a2014.0020"]}, {"Citation": "Lippi G, Montagnana M, Danese E, Favaloro EJ, Franchini M. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy. Biomark Med. 2011;5(1):63\u201370.", "ArticleIdList": ["21319966", "10.2217/bmm.10.119"]}, {"Citation": "Giordano A, Musumeci G, D\u2019Angelillo A, Rossini R, Zoccai GB, Messina S, et al. Effects of glycoprotein IIb/IIIa antagonists: anti platelet aggregation and beyond. Curr Drug Metab. 2016;17(2):194\u2013203.", "ArticleIdList": ["26652157", "10.2174/1389200217666151211121112"]}, {"Citation": "Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol. 2013;35(3):254\u201361.", "ArticleIdList": ["23590652", "10.1111/ijlh.12084"]}, {"Citation": "Lebas H, Yahiaoui K, Martos R, Boulaftali Y. Platelets are at the nexus of vascular diseases. Front Cardiovasc Med. 2019. https://doi.org/10.3389/fcvm.2019.00132 .", "ArticleIdList": ["10.3389/fcvm.2019.00132", "31572732", "6749018"]}, {"Citation": "McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol. 2018;15(3):181\u201391.", "ArticleIdList": ["29297508", "10.1038/nrcardio.2017.206"]}, {"Citation": "Ibbotson T, McGavin JK, Goa KL. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121\u201363.", "ArticleIdList": ["12749745", "10.2165/00003495-200363110-00014"]}, {"Citation": "De Luca G, Navarese EP, Cassetti E, Verdoia M, Suryapranata H. Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol. 2011;107(2):198\u2013203.", "ArticleIdList": ["21211597", "10.1016/j.amjcard.2010.08.063"]}, {"Citation": "Friedland S, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2011;108(9):1244\u201351.", "ArticleIdList": ["22000626", "10.1016/j.amjcard.2011.06.039"]}, {"Citation": "Global Organization Network BI. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation. 2002;105(3):316\u201321.", "ArticleIdList": ["10.1161/hc0302.102573"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "10", "Day": "11"}, {"Year": "2023", "Month": "1", "Day": "9"}, {"Year": "2023", "Month": "4", "Day": "13", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "1", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "1", "Day": "13", "Hour": "11", "Minute": "19"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36637623", "10.1007/s40292-023-00562-9", "10.1007/s40292-023-00562-9"]}}], "PubmedBookArticle": []}